Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Status:
Completed
Trial end date:
2020-10-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the safety and efficacy of Ruxolitinib in combination
with Trastuzumab in treatment of HER2 positive metastatic breast cancer. Ruxolitinib (Jakafi)
is an Food and Drug Administration (FDA) approved treatment for myelofibrosis (a disease of
the bone marrow), but its safety and efficacy in breast cancer patients is not known.
Trastuzumab (Herceptin) is an FDA-approved treatment for HER2 positive breast cancer. The
safety and efficacy of both treatments given in combination is not known. It is hypothesized
that Ruxolitinib in combination with Trastuzumab will demonstrate efficacy in treating
Metastatic HER2 Positive Breast Cancer subjects, and will have a tolerable safety profile in
this patient population.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Dawn L. Hershman Kevin Kalinsky
Collaborators:
Incyte Corporation National Cancer Institute (NCI)